Category: CNS

  • It’s time to do better for patients with rare neurological disorders

    Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to clinical trials for all patients with rare CNS conditions. Rare diseases impact more than 30 million Americans, and 400 million people around the globe. Less than 5% of the more than 7,000 rare diseases have approved treatments. […]

  • 3rd Annual Blood-Brain Barrier Summit

    The 3rd Annual Blood-Brain Barrier Summit is dedicated to helping drug developers enhance drug delivery across the Blood-Brain Barrier (BBB) to enable effective treatments for neurodegenerative diseases. Now in its third year, this digital forum is the industry’s definitive blood-brain barrier conference, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for […]

  • The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

    The Blood-Brain Barrier Summit will take place online from June 28-30, 2021. This Hanson Wade event is aimed at experts looking to deliver CNS drug candidates safely and successfully across the blood-brain barrier (BBB). It will enable them understand the biology of the BBB, explore the latest technological innovations and develop more predictive preclinical models. […]

  • 2nd Gene Therapy for Neurological Disorders Europe

    Returning digitally in 2021, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! Focusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation, this is not one to miss […]

  • Nine for 2021: Addressing the pandemic legacy

    In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: the permanent changes in customer engagement models, the implications of a geographic re-balancing towards the East, CNS as the new value growth area for the 2020s, and the new biologics environment as biosimilars accelerate. […]